PFO Dr Peter Wilmshurst Royal Shrewsbury Hospital Co-workers: Simon Nightingale, Lindsay Morrison, Matthew Pearson, Kevin Walsh, Phil Bryson, John Davis,

Slides:

Advertisements

Similar presentations

Acyanotic Heart Disease PRECIOUS PEDERSEN INTRODUCTION Left to right shunting lesions, increased pulmonary blood flow The blood is shunted through.

Advertisements

“PFO Closure: anatomical variants and implications for choice of procedure, success rates and complications” LM Shapiro. Papworth Hospital, Cambridge.

Neurologic Origins of Dizziness & Vertigo Clinical presentations of Dizziness or Vertigo that is of Neurologic Origin  Neurologically mediated dizziness.

Teaching Evidence-Based Medicine Gary S Gronseth, MD, FAAN Professor of Neurology University of Kansas.

PFO CLOSURE JOURNAL REVIEW OF EVIDENCE.  PFO is a remnant of fetal circulation  At autopsy-Identified in 27% of normal patients  Prevalence decline.

PFO CLOSURE JOURNAL REVIEW OF EVIDENCE.  PFO is a remnant of fetal circulation  Identified in 27% of normal patients at autopsy  Prevalence decline.

Richard Leigh, M.D. Johns Hopkins University School of Medicine.

Indications for intervention of ASD and VSD

Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.

MIST I & III Studies Andrew J. Dowson Director Headache Services King’s College Hospital London, UK For the MIST investigators.

Percutaneous Closure of Patent Foramen Ovale Sponsors: Kung Ming Jan, M.D., Ph.D. Judah Weinberger, M.D., Ph.D. Columbia University Medical Center Department.

DR. HANA OMER CONGENITAL HEART DEFECTS. The major development of the fetal heart occurs between the fourth and seventh weeks of gestation, and most congenital.

DEREK B. COVINGTON, M.D. RESIDENT PHYSICIAN – PGY2 DEPARTMENT OF ANESTHESIOLOGY UNIVERSITY OF MIAMI/JACKSON MEMORIAL HOSPITAL Modification of Individual.

Migraine Intervention with STARFlex Technology (MIST) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Andrew.

FOETAL CIRCULATION. CIRCULATION AFTER BIRTH EMBRYOLOGY Embryologically, the septum primum separates the two atria first, moving inferiorly toward the.

Atrial Septal Defect Dr. mahsa ghasemi.

Principal Groups of CHD

Atrial Fibrillation Warfarin and its newer alternatives

Transthoracic Echocardiography in Cerebrovascular Disease Nisha I Parikh, MD MPH Noninvasive Imaging Conference May 14 th 2008.

CONGENITAL DISEASES Dr. Meg-angela Christi Amores.

Percutaneous PFO Closure

PFO Closure: clear and borderline indications and cases where there is no evidence of benefit Michael Mullen Royal Brompton Hospital London.

To Close or Not to Close (the PFO)? That is the Question

Respiratory complications of obesity. Obesity has significant effects upon the pulmonary mechanics. BMI has a direct relationship with the degree of airways.

Congenital Heart Disease Most occur during weeks 3 to 8 Incidence 6 to 8 per 1,000 live born births Some genetic – Trisomies 13, 15, 18, & 21 and Turner.

Dr. M. A. Sofi MD; FRCP (London); FRCPEdin; FRCSEdin

UNEXPECTED CAUSE(S) OF CEREBRAL MICROEMBOLISATION INVESTIGATED BY TRANSCRANIAL DOPPLER DUPLEX COLOUR SONOGRAPHY Muriel SPRYNGER Cardiology-Angiology CHU.

UBC-Case 1 Samuel Yip PhD, MD, FRCPC Western Stroke Day 2012.

DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.

Transcatheter closure of patent foramen ovale with the Spider TM PFO Occluder:Initial Clinical Experience Department of Cardiology, Guangdong Cardiovascular.

Update on TIA Kath Pasco October  Primary prevention has been effective in fall in incidence of first stroke  Major improvements still required.

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Presenter disclosure information name: Frank Uhlemann In the last 12 month.

Long-Term Comparison of Medical Treatment With Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolism: A Propensity-Score.

CONGENITAL HEART DEFECTS DR. HANA OMER. CONGENITAL HEART DEFECTS D. HANA OMER.

Dr. M. A. Sofi MD; FRCP (London); FRCPEdin; FRCSEdin

PFO Closure : a critical overview of recent data Ramesh Daggubati, MD FACC FSCAI Director of Interventional Cardiology East Carolina University Greenville,

Why Should We Treat PFO? SCAI Interventional Cardiology Fellows Course

Cardioembolic Stroke: Diagnosis and Management

Disclosure Statement of Financial Interest

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Persistence of Iatrogenic Atrial Septal Defect After.

Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.

Atrial Septal Defect R3 이재연.

POSTER 1 7:10 – 7:17 Initial Clinical Experience with the GORE® CARDIOFORM ASD Occluder for Transcatheter Atrial Septal Defect Closure Presenter: Quentin.

Update on PFO Closures Mark Reisman, M.D., F.A.C.C.

PFO Closure: Review of the Trials for Migraine CRT 2013

PFO and Decompression Illness in Recreational Divers

PFO closure: Review of the Trials for Migraine

Dr. M. A. Sofi MD; FRCP (London); FRCPEdin; FRCSEdin

Figure 1: Animal preparation; a modified Glenn shunt was created between the SVC and the main pulmonary artery. A left ventricular assist device was implanted.

PFO FDA Considerations for Labeling and Future Trials

David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators

Challenging Case Presentation For Structural Heart Disease Program

Successful retrieval of embolized atrial septal defect and patent foramen ovale closure device using novel coronary wire trap (CWT) technique. Alireza.

Update on PFO Trials Michael S. Kim, MD, FACC, FSCAI

A Primer of LAA Closure: and Pattern Recognition

2 A Cardiology Department, University of Athens

Patent Foramen Ovale Devices and Trials Update: Is the Current Data Sufficient for Approval? CRT 2017 Feb18-21, 2017 Steven L. Goldberg, MD Medical.

Incidence of May-Thurner Syndrome in Patients undergoing Patent Foramen Ovale Closure for Cryptogenic Stroke Thomas J. Kiernan MD, Bryan P Yan MD, Pablo.

A Primer of LAA Closure: and Pattern Recognition

A Case of Recurrent Ischemic Stroke due to Paradoxical Embolism through Different Channels Dong-geun Lee, M.D., Seungyoo Kim, M.D., Jae Young An, M.D.,

Silent No More:.

Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.

Patent Foramen Ovale and Stroke

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

Volume 110, Issue 5, Pages (November 1996)

This subcostal four-chamber view demonstrates how the pulmonary veins join at the confluence (pulmonary venous confluence, PVC) before draining anomalously.

Surgical management of complications after transcatheter closure of an atrial septal defect or patent foramen ovale Pascal A. Berdat, MDa, Tushar Chatterjee,

To Reduce Stroke with PFO Closure, Respect the Shunt

Classification of congenital heart diseases

Presentation transcript:

PFO Dr Peter Wilmshurst Royal Shrewsbury Hospital Co-workers: Simon Nightingale, Lindsay Morrison, Matthew Pearson, Kevin Walsh, Phil Bryson, John Davis, J de Giovanni, Chris Byrne and MIST Trial investigators

NO CONFLICT OF INTEREST TO DECLARE

Syndromes associated with right to left shunts Paradoxical thromboembolism and stroke (atrial >>>>> pulmonary shunts)

Syndromes associated with right to left shunts Paradoxical thromboembolism and stroke (atrial >>>>> pulmonary shunts) Paradoxical gas embolism and decompression illness (atrial >> pulmonary shunts)

Syndromes associated with right to left shunts Paradoxical thromboembolism and stroke (atrial >>>>> pulmonary shunts) Paradoxical gas embolism and decompression illness (atrial >> pulmonary shunts) Migraine with aura (atrial > pulmonary shunts)

Syndromes associated with right to left shunts Paradoxical thromboembolism and stroke (atrial >>>>> pulmonary shunts) Paradoxical gas embolism and decompression illness (atrial >> pulmonary shunts) Migraine with aura (atrial > pulmonary shunts) Arterial hypoxaemia (pulmonary >>>>> atrial shunts)

Prevalence of migraine with aura related to shunt size 4% of general population 4% of those with small right-to-left shunts 25% of those with medium shunts at rest 21% of those with large shunt with Valsalva 53% of those with large shunt at rest 53% of those with Hereditary Haemorrhagic Telangiectasia

Determinants of size of the shunt through a PFO Dimensions of the foramen Size of the flap Compliance of the flap Pressure gradient* Atrial flow characteristics* *variable

Migraine with aura and increased incidence of cryptogenic stroke Large atrial shunts (PFO & ASD) are present in: 7.3% - population controls 38.1% - migraine with aura but no stroke 84% - stroke and migraine with aura (Am J Card 2006;98:831-3)

Migraine with aura and risk of decompression illness People with migraine with aura have increased risk of neurological DCI (War Medicine 1944;5:304-14) The increased risk is confined to migraineurs with a large PFO or other large right-to-left shunt (Clinical Science 2001;100:215-20).

Recurrence of symptoms after PFO closure Symptoms are not shunt-related and PFO is bystander.

Recurrence of symptoms after PFO closure Symptoms are not shunt-related and PFO is bystander. PFO closure device responsible for recurrence (e.g. migraine triggering effect of device, stroke caused by thrombus on device or AF post implantation).

Recurrence of symptoms after PFO closure Symptoms are not shunt-related and PFO is bystander. PFO closure device responsible for recurrence (e.g. migraine triggering effect of device, stroke caused by thrombus on device or AF post implantation). Significant residual shunt through PFO, another atrial defect or a pulmonary shunt.